One Test, Multiple Targets: Zeroing in on Autoimmune Movement Disorders - Insights
A movement disorder might be caused by the body’s immune system, which is meant to fight infections, suddenly attacking the brain. Fortunately, an “autoimmune movement disorder” can often be treated—once its cause is discovered.
Mayo Clinic Ranked No. 1 Hospital Nationwide by U.S. News & World Report - Insights
Mayo Clinic was named the best hospital in the nation in U.S. News & World Report’s 29th annual "Best Hospitals Honor Roll" published online on August 14. Mayo Clinic also ranked No. 1 in more specialties than any other hospital in the...
October 2023 - Gynecological Pathology and Surgical Pathology - Insights
This "Pathways" program provides an Anatomic Pathology case that includes a history, potential answers, rationale, and relevant references. This case’s sub-specialties are Gynecological Pathology and Surgical Pathology.
Pathways Case Studies: September 2019 - Insights
Mayo Clinic laboratory experts share five case studies in this month’s “PathWays” post and are challenging you to test your laboratory genetics & genomics, bone & soft tissue, renal, infectious disease, and gastroenterology pathology...
Respiratory viruses - Insights
Browse our full suite of serology and PCR testing for respiratory viruses like influenza, RSV, and more.
TPNUQ genotyping assay - Insights
Ann Moyer, M.D., Ph.D., discusses TPNUQ, Mayo Clinic Laboratories' genotyping test for identifying patients at risk for thiopurine toxicity. Used prior to therapy initiation, our assay evaluates for nuances in both TPMT and NUDT15, which...
Wei Shen, Ph.D., and Rhianna Urban, M.S., CGC, explain how Mayo Clinic Laboratories' gene panel establishes a diagnosis of Lynch syndrome, which heightens the risk for several cancers. Test results can guide targeted cancer surveillance for...
Focused Pharmacogenomics Panel [Test in Focus] - Insights
Ann Moyer, M.D., Ph.D., explains Mayo Clinic Labs’ new focused pharmacogenomics panel, a real-time, PCR-based testing approach that assesses 10 genes known for their drug-gene associations, to provide guidance on medication selection for...
Find out more about UBA1Q, a quantitative droplet digital polymerase chain reaction (ddPCR) assay that targets seven possible mutations that can occur in the UBA1 gene and help identify VEXAS syndrome.
Is the term "outreach" obsolete? - Insights
In a competitive outpatient testing market, choosing a laboratory is discretionary. With the goal of becoming the laboratory of choice for discretionary outpatient testing, it no longer matters if it is called “inreach” or “outreach.” While...